Full Press Release Details
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD).
ALT
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
Key Takeaway: Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
Price reaction · baseline $3.56 (2025-08-18 close) · hit after-hours · 1 other ALT headline(s) in the window, move may be shared
day 0 close
+1.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight